Developer docs
API playgroundTry for free, no card

Search company profiles

Cero Therapeutics

Full company profile

uuid0000eba

Namestring
Cero Therapeutics
Legal namestring
CERo Therapeutics, Inc.
Websiteurl
cero.bio
Company typeenum
Public
Founded yearint
2016
Descriptiontext

CERo Therapeutics, Inc. is a clinical-stage cellular immunotherapy company developing engineered T-cell therapies for cancer based on its proprietary Chimeric Engulfment Receptor (CER-T) platform. The company's lead product candidate, CER-1236, is an autologous T-cell therapy engineered with a chimeric engulfment receptor that combines a phagocyte extracellular domain — which binds phosphatidylserine ("Eat Me") signals externalized on tumor cells — with intracellular T-cell signaling and antigen-presentation domains. This architecture is designed to deliver direct cytotoxic killing while simultaneously stimulating adaptive immune responses through antigen processing and presentation within a single T cell, with the company positioning the approach as a way to avoid target-negative tumor escape and the cytokine release syndrome / neurotoxicity observed in conventional CAR-T therapies.

CERo is currently running the Phase 1 CERTAIN-T trial of CER-1236 in hematologic malignancies. As of mid-2026, six patients had been dosed across escalating cohorts with no dose-limiting toxicities, no observed cases of cytokine release syndrome or neurotoxicity, in vivo cell expansion of 20-70 fold peaking between days 7-14, and at least one patient achieving sustained platelet transfusion independence followed by successful allogeneic stem cell transplantation. The trial was expanded under FDA clearance to include myelodysplastic syndrome (MDS) and myelofibrosis patients, and CERo has refocused its development strategy around MDS. A pre-clinical solid tumor program using the same CER-T platform is also disclosed. The company received FDA Orphan Drug Designation for CER-1236 in AML in June 2025.

The company generates no revenue and operates a pre-commercial clinical-stage business model. Future revenue is expected to derive from product sales or licensing following regulatory approval, with cell therapy distribution anticipated to require specialized hospital pharmacies or specialty distributors with cryogenic handling capabilities. The company is headquartered in South San Francisco, California, employs a small team (1-10 per firmographic disclosures), and is publicly traded under ticker CERO. Following a Nasdaq listing determination of non-compliance in October 2025, shares moved to OTCQB in December 2025; the company has engaged an investment bank to pursue a Nasdaq relisting while relying on lead investor convertible debt funding and small Series D tranches ($5M in February 2025 and up to $8M in April 2025) to extend its cash runway.

Short descriptiontext

CERo Therapeutics is a clinical-stage cellular immunotherapy company developing engineered T-cell therapies using its proprietary Chimeric Engulfment Receptor (CER-T) platform, with lead candidate CER-1236 in Phase 1 trials for acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy immunotherapy, engineered T cells, hematologic cancer treatment, chimeric receptor platform, cell therapy oncology
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Cancer Immunotherapy
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, CERo does not currently generate revenue. The company is developing CER-1236 for hematologic malignancies with plans to advance through clinical trials and seek regulatory approval for commercialization. Future revenue will derive from product sales following FDA approval.

tradingview.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CERo Therapeutics develops engineered autologous T cell therapies for cancer using its proprietary Chimeric Engulfment Receptor T (CER-T) cell platform, which integrates innate (phagocytosis/antigen presentation) and adaptive (T-cell cytotoxicity) immune mechanisms into a single T cell. The lead product candidate CER-1236 is in Phase 1 clinical trials for hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis, with a pre-clinical program for solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • No dose-limiting toxicities observed across six patients treated in Phase 1 trial
+4 more records
Product overview1 text field

Cero Therapeutics is developing a portfolio of CER T-cell (Chimeric Engulfment Receptor T cell) products based on its proprietary technology platform. The company's lead product is CER-1236, which targets hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis. The platform technology engineers T cells to combine attributes of both innate (engulfment and antigen presentation) and adaptive (T-cell activation) immune systems for enhanced anti-tumor responses. The company also has a pre-clinical solid tumor program using the same CER-1236 technology.

Product and service3 records
1CER-1236 (Lead Program)
CategoryCell Therapy Product Candidate
Description

Lead CER T-cell product candidate targeting hematologic malignancies, particularly acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis. Engineered with chimeric engulfment receptor technology to combine innate and adaptive immune responses against tumor cells.

2CER T-Cell Platform
CategoryTechnology Platform
Description

Proprietary autologous cell therapy platform engineering T cells with chimeric engulfment receptors that target cancer cells' 'eat me' signals (phosphatidylserine). Combines direct cell killing and phagocytic antigen presentation into single T cells for treatment of hematologic and solid tumors.

3CER-1236 Solid Tumor Program
CategoryCell Therapy Product Candidate
Description

CER T-cell product candidate for solid tumor indications leveraging the CER-T platform mechanism that may overcome solid tumor microenvironment barriers, currently in pre-clinical stage.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer targeting hematologic malignancies and solid tumors. Highly comparable to CERo as a cell therapy biotech with platform-level ambition, though focused on off-the-shelf rather than autologous approaches.

TypeDirect peer
Description

Clinical-stage allogeneic CAR-T developer using CRISPR-based genome editing for hematologic malignancies. Closely comparable as a clinical-stage engineered T-cell therapy company with a platform approach.

TypeDirect peer
Description

Clinical-stage cell therapy developer using ARCUS gene editing to create allogeneic CAR-T candidates for hematologic malignancies. Comparable in stage, modality, and target indications.

TypeDirect peer
Description

Clinical-stage allogeneic T-cell therapy developer (tab-cel, tabelecleucel) targeting hematologic malignancies and viral-associated diseases. Directly comparable as a small-cap public cell therapy biotech.

TypeDirect peer
Description

Clinical-stage cell therapy developer working on CAR-T and TCR-based therapies for hematologic malignancies and solid tumors. Comparable in scale, modality, and clinical-stage profile.

TypeBroad incumbent
Description

Clinical/commercial-stage engineered T-cell therapy company with approved TCR-T product (Tecelra). Comparable as a public cell therapy biotech working on novel receptor-based T-cell engineering, though at a more advanced commercial stage.

TypeEmerging player
Description

Clinical-stage cell therapy company focused on solid tumor CAR-T and TCR-T programs. Directly comparable as a next-generation cell therapy biotech, and was a prior CERo investor.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T developer using TALEN gene editing. Comparable as a pioneering engineered T-cell therapy platform pursuing both hematologic and solid tumor indications.

9CARsgen Therapeutics
TypeEmerging player
Description

Clinical/commercial-stage CAR-T developer (zevorcabtagene autoleucel approved in China for multiple myeloma) with pipeline in hematologic malignancies and solid tumors. Comparable cell therapy modality and indications.

TypeBroad incumbent
Description

Commercial-stage gene-edited cell therapy company (Casgevy approved for sickle cell disease and beta-thalassemia). Comparable as an engineered cell therapy platform company, though more advanced and broader in scope.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cero Therapeutics

Cell Therapy / Cancer Immunotherapycero.bio

CERo Therapeutics is a clinical-stage cellular immunotherapy company developing engineered T-cell therapies using its proprietary Chimeric Engulfment Receptor (CER-T) platform, with lead candidate CER-1236 in Phase 1 trials for acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis.

What Cero Therapeutics does

CERo Therapeutics, Inc. is a clinical-stage cellular immunotherapy company developing engineered T-cell therapies for cancer based on its proprietary Chimeric Engulfment Receptor (CER-T) platform. The company's lead product candidate, CER-1236, is an autologous T-cell therapy engineered with a chimeric engulfment receptor that combines a phagocyte extracellular domain — which binds phosphatidylserine ("Eat Me") signals externalized on tumor cells — with intracellular T-cell signaling and antigen-presentation domains. This architecture is designed to deliver direct cytotoxic killing while simultaneously stimulating adaptive immune responses through antigen processing and presentation within a single T cell, with the company positioning the approach as a way to avoid target-negative tumor escape and the cytokine release syndrome / neurotoxicity observed in conventional CAR-T therapies.

CERo is currently running the Phase 1 CERTAIN-T trial of CER-1236 in hematologic malignancies. As of mid-2026, six patients had been dosed across escalating cohorts with no dose-limiting toxicities, no observed cases of cytokine release syndrome or neurotoxicity, in vivo cell expansion of 20-70 fold peaking between days 7-14, and at least one patient achieving sustained platelet transfusion independence followed by successful allogeneic stem cell transplantation. The trial was expanded under FDA clearance to include myelodysplastic syndrome (MDS) and myelofibrosis patients, and CERo has refocused its development strategy around MDS. A pre-clinical solid tumor program using the same CER-T platform is also disclosed. The company received FDA Orphan Drug Designation for CER-1236 in AML in June 2025.

The company generates no revenue and operates a pre-commercial clinical-stage business model. Future revenue is expected to derive from product sales or licensing following regulatory approval, with cell therapy distribution anticipated to require specialized hospital pharmacies or specialty distributors with cryogenic handling capabilities. The company is headquartered in South San Francisco, California, employs a small team (1-10 per firmographic disclosures), and is publicly traded under ticker CERO. Following a Nasdaq listing determination of non-compliance in October 2025, shares moved to OTCQB in December 2025; the company has engaged an investment bank to pursue a Nasdaq relisting while relying on lead investor convertible debt funding and small Series D tranches ($5M in February 2025 and up to $8M in April 2025) to extend its cash runway.

Cero Therapeutics firmographics

Firmographics
Name
Cero Therapeutics
Legal name
CERo Therapeutics, Inc.
Website
https://cero.bio
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
CERo Therapeutics is a clinical-stage cellular immunotherapy company developing engineered T-cell therapies using its proprietary Chimeric Engulfment Receptor (CER-T) platform, with lead candidate CER-1236 in Phase 1 trials for acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis.
Ownership category
akta.pro rank

Cero Therapeutics industry classification

Industry
Product category
Cell Therapy / Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Cell therapy immunotherapy
  • Engineered T cells
  • Hematologic cancer treatment
  • Chimeric receptor platform
  • Cell therapy oncology

Where Cero Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cero Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Cell Therapy Development and Commercialization: As a clinical-stage biopharmaceutical company, CERo does not currently generate revenue. The company is developing CER-1236 for hematologic malignancies with plans to advance through clinical trials and seek regulatory approval for commercialization. Future revenue will derive from product sales following FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cero Therapeutics product offering

Product offering

Core offering

CERo Therapeutics develops engineered autologous T cell therapies for cancer using its proprietary Chimeric Engulfment Receptor T (CER-T) cell platform, which integrates innate (phagocytosis/antigen presentation) and adaptive (T-cell cytotoxicity) immune mechanisms into a single T cell. The lead product candidate CER-1236 is in Phase 1 clinical trials for hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis, with a pre-clinical program for solid tumors.

Product overview

Cero Therapeutics is developing a portfolio of CER T-cell (Chimeric Engulfment Receptor T cell) products based on its proprietary technology platform. The company's lead product is CER-1236, which targets hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis. The platform technology engineers T cells to combine attributes of both innate (engulfment and antigen presentation) and adaptive (T-cell activation) immune systems for enhanced anti-tumor responses. The company also has a pre-clinical solid tumor program using the same CER-1236 technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • CER-1236 (Lead Program) Lead CER T-cell product candidate targeting hematologic malignancies, particularly acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis. Engineered with chimeric engulfment receptor technology to combine innate and adaptive immune responses against tumor cells.
  • CER T-Cell Platform Proprietary autologous cell therapy platform engineering T cells with chimeric engulfment receptors that target cancer cells' 'eat me' signals (phosphatidylserine). Combines direct cell killing and phagocytic antigen presentation into single T cells for treatment of hematologic and solid tumors.
  • CER-1236 Solid Tumor Program CER T-cell product candidate for solid tumor indications leveraging the CER-T platform mechanism that may overcome solid tumor microenvironment barriers, currently in pre-clinical stage.

Quantifiable outcome

  • No dose-limiting toxicities observed across six patients treated in Phase 1 trial
  • +4 more outcomes

Companies that use Cero Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Cero Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cero Therapeutics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Cero Therapeutics competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer targeting hematologic malignancies and solid tumors. Highly comparable to CERo as a cell therapy biotech with platform-level ambition, though focused on off-the-shelf rather than autologous approaches.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-based genome editing for hematologic malignancies. Closely comparable as a clinical-stage engineered T-cell therapy company with a platform approach.
  • Precision BioSciences: Clinical-stage cell therapy developer using ARCUS gene editing to create allogeneic CAR-T candidates for hematologic malignancies. Comparable in stage, modality, and target indications.
  • Atara Biotherapeutics: Clinical-stage allogeneic T-cell therapy developer (tab-cel, tabelecleucel) targeting hematologic malignancies and viral-associated diseases. Directly comparable as a small-cap public cell therapy biotech.
  • Celyad Oncology: Clinical-stage cell therapy developer working on CAR-T and TCR-based therapies for hematologic malignancies and solid tumors. Comparable in scale, modality, and clinical-stage profile.

Broad incumbents

  • Adaptimmune Therapeutics: Clinical/commercial-stage engineered T-cell therapy company with approved TCR-T product (Tecelra). Comparable as a public cell therapy biotech working on novel receptor-based T-cell engineering, though at a more advanced commercial stage.
  • CRISPR Therapeutics: Commercial-stage gene-edited cell therapy company (Casgevy approved for sickle cell disease and beta-thalassemia). Comparable as an engineered cell therapy platform company, though more advanced and broader in scope.

Emerging players

  • Lyell Immunopharma: Clinical-stage cell therapy company focused on solid tumor CAR-T and TCR-T programs. Directly comparable as a next-generation cell therapy biotech, and was a prior CERo investor.
  • Cellectis: Clinical-stage allogeneic CAR-T developer using TALEN gene editing. Comparable as a pioneering engineered T-cell therapy platform pursuing both hematologic and solid tumor indications.
  • CARsgen Therapeutics: Clinical/commercial-stage CAR-T developer (zevorcabtagene autoleucel approved in China for multiple myeloma) with pipeline in hematologic malignancies and solid tumors. Comparable cell therapy modality and indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cero Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cero Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Cero Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cero Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cero Therapeutics

What does Cero Therapeutics do?

CERo Therapeutics develops engineered autologous T cell therapies for cancer using its proprietary Chimeric Engulfment Receptor T (CER-T) cell platform, which integrates innate (phagocytosis/antigen presentation) and adaptive (T-cell cytotoxicity) immune mechanisms into a single T cell. The lead product candidate CER-1236 is in Phase 1 clinical trials for hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myelofibrosis, with a pre-clinical program for solid tumors.

Is Cero Therapeutics a public or private company?

Cero Therapeutics is a public company. It is classified as public and is currently operating.

When was Cero Therapeutics founded?

Cero Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Cero Therapeutics based?

Cero Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Cero Therapeutics make money?

One revenue line is on record: cell Therapy Development and Commercialization.

Who are Cero Therapeutics's main competitors?

Direct peers on record are Allogene Therapeutics, Caribou Biosciences, Precision BioSciences, Atara Biotherapeutics and Celyad Oncology. Broad incumbents are Adaptimmune Therapeutics and CRISPR Therapeutics. Emerging players are Lyell Immunopharma, Cellectis and CARsgen Therapeutics.

Does Cero Therapeutics have an API?

No public API is recorded for Cero Therapeutics.

What industry is Cero Therapeutics in?

Cero Therapeutics's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeSRX Global Comments on Pfizer’s Starna Deal, Highlights Interest in Engineered T-Cell Therapies and CERo Acquisition Update | SRXH Stock NewsSRX Global commented on Pfizer's $330 million upfront investment in Starna's CAR-T programs and updated its pending acquisition of CERo Therapeutics. CERo's lead candidate CER-1236 is in a Phase 1/1b trial with seven patients dosed, reporting no dose-limiting toxicities. SRX does not view the Pfizer deal as a valuation benchmark for CERo.Stock TitanSRX Global: CERo Acquisition Pending, 7th Patient DosedSRX Global commented on Pfizer's $330 million upfront licensing deal with Starna for three pre-IND CAR-T programs and its pending acquisition of CERo Therapeutics. CERo's lead candidate CER-1236 has seven patients dosed in the Phase 1/1b CERTAIN-T trial, with no dose-limiting toxicities reported. SRX expects to close the acquisition.TradingViewSRX Global Inc. (SRXH) Reports Seven Patients Dosed in CERo TrialSRX Global reported seven patients dosed in the Phase 1/1b CERTAIN-T trial of CER-1236, with preliminary results. No dose-limiting toxicities were seen in three patients, and the proposed acquisition of CERo remains pending.TradingViewCERo Therapeutics 3Q 2026: EPS $0 — 10-Q SummaryCERo Therapeutics reported net income of $4.02 million for Q3 2026, turning from a $11.51 million loss, with no revenue. R&D expenses fell 17.3% to $1.97 million and G&A expenses dropped 38.3% to $1.22 million. The company agreed to sell its operating subsidiary to SRX on October 6.TradingViewSRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic MalignanciesSRX Global activated UC Davis as a clinical trial site for CERo Therapeutics' Phase 1 CERTAIN-T study of CER-1236 in hematologic malignancies. UC Davis also serves as the primary manufacturing site, expected to expand patient recruitment and streamline logistics. The study has expanded to include myelodysplastic syndromes and myelofibrosis.GlobeNewswireSRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic MalignanciesSRX Global announced that UC Davis is activated as a clinical trial site for the Phase 1 CERTAIN-T study of CER-1236 in hematologic malignancies. UC Davis also serves as the primary manufacturing site, expected to expand patient recruitment and streamline logistics. The activation follows SRX's definitive agreement to acquire CERo Therapeutics.Stock TitanSRX Global activates UC Davis site for CERo Phase 1 trialSRX Global activated UC Davis as a clinical trial site for CERo Therapeutics' Phase 1 CERTAIN-T study of CER-1236 in hematologic malignancies. UC Davis also serves as the primary manufacturing site, expected to expand patient recruitment and streamline logistics. The proposed acquisition of CERo remains pending.Stock TitanSRX Global Agrees to Acquire CERo TherapeuticsSRX Global entered a definitive agreement to acquire CERo Therapeutics, making it a wholly owned subsidiary. The deal aims to accelerate development of CER-1236 for hematologic malignancies, with CERo reporting no dose-limiting toxicities in the latest trial cohort. The third planned cohort is screening for enrollment.TradingViewSRX Global Provides Up to $6.0 Million in New Advances Under $11.67 Million Secured Note to CERo TherapeuticsSRX Global completed a secured financing with CERo Therapeutics Holdings on August 27, 2026, consolidating $5.67 million in prior notes and permitting up to $6.0 million in new advances, for a total of $11.67 million. An initial $775,665 was funded at signing, with the note accruing 10% interest and maturing October 15, 2026, extendable by four 30-day periods.YahooSRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic CancersSRX Global acquired senior secured debt in CERo Therapeutics Holdings, an engineered T cell immunotherapy company. The investment aims to accelerate development of CER-1236 for hematologic cancers, with CERo having treated six patients in the Phase 1 CERTAIN-T trial and no dose-limiting toxicities observed in the most recent cohort.